Total Payments
$2.4M
2024 Payments
$125,791
Companies
30
Transactions
1,831
Payment Breakdown by Category
Consulting$1.3M (52.4%)
Other$908,666 (37.7%)
Travel$203,970 (8.5%)
Food & Beverage$26,659 (1.1%)
Research$6,980 (0.3%)
Education$120.88 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $1.3M | 141 | 52.4% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $846,854 | 324 | 35.2% |
| Travel and Lodging | $203,970 | 698 | 8.5% |
| Honoraria | $53,227 | 41 | 2.2% |
| Food and Beverage | $26,659 | 607 | 1.1% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $8,585 | 1 | 0.4% |
| Unspecified | $6,980 | 6 | 0.3% |
| Education | $120.88 | 13 | 0.0% |
Payments by Type
General
$2.4M
1,825 transactions
Research
$6,980
5 transactions
Ownership
$0
1 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $764,387 | 94 | $0 (2024) |
| ABBVIE INC. | $480,836 | 519 | $0 (2024) |
| PFIZER INC. | $441,245 | 465 | $0 (2024) |
| Lilly USA, LLC | $119,262 | 155 | $0 (2022) |
| Celgene Corporation | $108,410 | 115 | $0 (2019) |
| Novartis Pharmaceuticals Corporation | $83,784 | 126 | $0 (2024) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $71,142 | 25 | $0 (2023) |
| Merck Sharp & Dohme Corporation | $60,571 | 56 | $0 (2019) |
| United Rheumatology | $38,750 | 7 | $0 (2021) |
| UCB, Inc. | $38,210 | 38 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $125,791 | 184 | PFIZER INC. ($57,758) |
| 2023 | $107,485 | 150 | ABBVIE INC. ($44,388) |
| 2022 | $88,864 | 129 | ABBVIE INC. ($48,127) |
| 2021 | $365,213 | 49 | Janssen Scientific Affairs, LLC ($307,000) |
| 2020 | $522,290 | 108 | Janssen Scientific Affairs, LLC ($368,781) |
| 2019 | $491,033 | 444 | AbbVie, Inc. ($150,221) |
| 2018 | $354,677 | 405 | AbbVie, Inc. ($99,688) |
| 2017 | $353,063 | 362 | PFIZER INC. ($193,295) |
All Payment Transactions
1,831 individual payment records from CMS Open Payments — Page 1 of 74
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/25/2024 | PFIZER INC. | XELJANZ (Drug) | Travel and Lodging | In-kind items and services | $1,047.38 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 12/21/2024 | PFIZER INC. | XELJANZ (Drug) | Travel and Lodging | In-kind items and services | $278.00 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 12/20/2024 | PFIZER INC. | XELJANZ (Drug) | Travel and Lodging | In-kind items and services | $136.01 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 12/19/2024 | ABBVIE INC. | RINVOQ (Biological) | Travel and Lodging | In-kind items and services | $1,551.83 | General |
| Category: IMMUNOLOGY | ||||||
| 12/19/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $86.89 | General |
| Category: IMMUNOLOGY | ||||||
| 12/19/2024 | PFIZER INC. | XELJANZ (Drug) | Travel and Lodging | In-kind items and services | $54.00 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 12/19/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $16.36 | General |
| Category: IMMUNOLOGY | ||||||
| 12/18/2024 | PFIZER INC. | XELJANZ (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,125.00 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 12/18/2024 | PFIZER INC. | XELJANZ (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,000.00 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 12/18/2024 | PFIZER INC. | XELJANZ (Drug) | Travel and Lodging | In-kind items and services | $65.28 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 12/18/2024 | PFIZER INC. | XELJANZ (Drug) | Food and Beverage | In-kind items and services | $23.80 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 12/17/2024 | PFIZER INC. | XELJANZ (Drug) | Food and Beverage | In-kind items and services | $10.76 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 12/10/2024 | UCB, Inc. | Bimzelx (Biological) | Travel and Lodging | Cash or cash equivalent | $139.57 | General |
| Category: Immunology | ||||||
| 12/10/2024 | UCB, Inc. | Bimzelx (Biological) | Travel and Lodging | Cash or cash equivalent | $83.96 | General |
| Category: Immunology | ||||||
| 12/04/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | In-kind items and services | $114.30 | General |
| Category: Immunology | ||||||
| 12/03/2024 | UCB, Inc. | Bimzelx (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $6,000.00 | General |
| Category: Immunology | ||||||
| 11/26/2024 | UCB, Inc. | Bimzelx (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $6,000.00 | General |
| Category: Immunology | ||||||
| 11/26/2024 | UCB, Inc. | Bimzelx (Biological) | Travel and Lodging | Cash or cash equivalent | $35.95 | General |
| Category: Immunology | ||||||
| 11/26/2024 | UCB, Inc. | Bimzelx (Biological) | Travel and Lodging | Cash or cash equivalent | $27.76 | General |
| Category: Immunology | ||||||
| 11/26/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | Cash or cash equivalent | $4.33 | General |
| Category: Immunology | ||||||
| 11/21/2024 | UCB, Inc. | Bimzelx (Biological) | Travel and Lodging | In-kind items and services | $628.47 | General |
| Category: Immunology | ||||||
| 11/21/2024 | UCB, Inc. | Bimzelx (Biological) | Travel and Lodging | In-kind items and services | $516.53 | General |
| Category: Immunology | ||||||
| 11/21/2024 | UCB, Inc. | Bimzelx (Biological) | Travel and Lodging | In-kind items and services | $241.10 | General |
| Category: Immunology | ||||||
| 11/19/2024 | PFIZER INC. | XELJANZ (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,125.00 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 11/19/2024 | PFIZER INC. | XELJANZ (Drug) | Travel and Lodging | In-kind items and services | $297.72 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| TOFACITINIB CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $3,980 | 2 |
| A Study to Investigate the Safety and Efficacy of Elsubrutinib and Upadacitinib Given Alone or in Combination in Participants With Moderately to Severely Active Systemic Lupus Erythematosus (SLE) | ABBVIE INC. | $500.00 | 1 |
| Phase 3B Study to Evaluate the Cardiovascular Safety of Febuxostat and Allopurinol in Gout Subjects With Cardiovascular Comorbidities and Hyperuricemia | Takeda Development Center Americas, Inc. | $500.00 | 1 |
About Dr. Allan Gibofsky, MD
Dr. Allan Gibofsky, MD is a Rheumatology healthcare provider based in New York, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 01/06/2007. The National Provider Identifier (NPI) number assigned to this provider is 1467500611.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Allan Gibofsky, MD has received a total of $2.4M in payments from pharmaceutical and medical device companies, with $125,791 received in 2024. These payments were reported across 1,831 transactions from 30 companies. The most common payment nature is "Consulting Fee" ($1.3M).
Ad
Practice Information
- Specialty Rheumatology
- Location New York, NY
- Active Since 01/06/2007
- Last Updated 04/12/2021
- Taxonomy Code 207RR0500X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1467500611
Products in Payments
- SIMPONI ARIA (Biological) $751,531
- XELJANZ (Drug) $255,966
- Humira (Biological) $126,375
- Otezla (Drug) $124,151
- RINVOQ (Biological) $117,188
- OLUMIANT (Drug) $81,824
- INFLECTRA (Biological) $77,041
- COSENTYX (Biological) $66,054
- RINVOQ (Drug) $36,183
- RENFLEXIS (Biological) $32,033
- Rinvoq (Biological) $30,816
- Bimzelx (Biological) $29,871
- Uloric (Drug) $28,653
- Zilretta (Drug) $25,735
- ENBREL (Biological) $22,069
- TRADJENTA (Drug) $18,904
- SKYRIZI (Biological) $13,958
- KRYSTEXXA (Drug) $13,680
- ORENCIA (Biological) $13,282
- TREMFYA (Drug) $12,856
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Rheumatology Doctors in New York
Laurie Glimcher, Md, MD
Rheumatology — Payments: $8.3M
Rheumatology $8.3M
Dr. Grace Wright, Md, MD
Rheumatology — Payments: $3.7M
Rheumatology $3.7M
Sergio Schwartzman, M.d, M.D
Rheumatology — Payments: $3.5M
Rheumatology $3.5M
Petros Efthimiou, Md, MD
Rheumatology — Payments: $1.2M
Rheumatology $1.2M
Dr. Olga Petryna, Md, MD
Rheumatology — Payments: $548,960
Rheumatology $548,960
Dr. Danielle Petersel, M.d, M.D
Rheumatology — Payments: $462,362
Rheumatology $462,362